Fresenius SE & Co. KGaA

Earnings Release • Nov 2, 2010

News Details

Ad-hoc | 2 November 2010 07:01

Fresenius SE: Fresenius reports excellent sales and earnings growth – raises outlook

Fresenius SE / Key word(s): Quarter Results

02.11.2010 07:01

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

Fresenius reports excellent sales and earnings growth - raises outlook

Group sales increased by 13% at actual rates and by 10% in constant
currency to EUR11,821 million (Q1-3/2009: EUR10,429 million). Organic sales
growth was 9%. Acquisitions contributed a further 1%. Currency translation
had a positive effect of 3%.

Group EBIT increased by 19% at actual rates and by 15% in constant currency
to EUR1,776 million (Q1-3/2009: EUR1,496 million). The EBIT margin
increased by 70 basis points to 15.0% (Q1-3/2009: 14.3%).

Group net income* increased by 35% at actual rates and by 30% in constant
currency to EUR495 million (Q1-3/2009: EUR368 million). Earnings per
ordinary share increased to EUR3.06 and earnings per preference share to
EUR3.07 (Q1-3/2009: ordinary share EUR2.28; preference share EUR2.29). This
represents an increase of 34% for both share classes.

Net income** (including special items) grew to EUR435 million, or EUR2.69
per ordinary share and EUR2.70 per preference share.

Based on the Group's excellent financial results in the first three
quarters, Fresenius now expects net income* to increase by around 20% in
constant currency in 2010. Previously, the Company expected net income to
increase by 10% to 15% in constant currency. Sales in constant currency are
now projected to increase by 8% to 9%. The previous guidance was 7% to 9%
in constant currency. The earnings outlook already includes expected
one-time expenses of EUR18 million to EUR20 million pre-tax which Fresenius
Kabi plans to invest in further efficiency improvements outside of North
America in 2010, of which EUR8 million are already included in the third
quarter results.

* Net income attributable to Fresenius SE; adjusted for the effects of
mark-to-market accounting of the Mandatory Exchangeable Bonds (MEB) and the
Contingent Value Rights (CVR) related to the acquisition of APP
Pharmaceuticals. Both are non-cash items.
** Net income attributable to Fresenius SE.

(Financial statements according to US GAAP)

The Management Board

Bad Homburg v.d.H., November 2, 2010

End of note

02.11.2010 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Fresenius SE
Else-Kröner-Straße 1
61352 Bad Homburg v.d.H.
Deutschland
Phone: +49 (0)6172 608-2485
Fax: +49 (0)6172 608-2488
E-mail: ir-fre@fresenius.com
Internet: www.fresenius.com
ISIN: DE0005785638, DE0005785604
WKN: 578563, 578560
Indices: DAX
Listed: Regulierter Markt in Frankfurt (Prime Standard), München,
Düsseldorf; Freiverkehr in Berlin, Stuttgart, Hannover,
Hamburg; Terminbörse EUREX

End of Announcement DGAP News-Service

---